Clinical Trials Logo

Clinical Trial Summary

The purpose of this registry is to find members of the Plain Community who are interested in participating in future medical research studies. Having a registry makes it easier to contact and offer study participation to individuals who are appropriate for a new research study based on their own and their family medical history. Studies will focus on increasing knowledge about disorders affecting those who are Amish and Mennonite.


Clinical Trial Description

The Amish and Mennonite communities of western Pennsylvania are unique because they are isolated both geographically and socially. These groups originally migrated as a small group from Europe. Since this first settlement there have been additional migration events within North America that have resulted in many distinct communities. These events lead to genetic founder effects, genetic bottleneck effects and virtually zero genetic inflow. The result has been an increased burden of genetic disease on these vulnerable communities. Specific founder genes explain the prevalence of different genetic conditions within each community and family group. This means that families and communities will have a clustering of certain genetic conditions, while the prevalence among the Plain people as a whole remains low. Understanding the specific needs of each family and community group is important in order to deliver comprehensive and specialized care. This requires research studies and needs assessments within these communities. Currently this need is being addressed in eastern Pennsylvania by the Clinic for Special Children in Strasburg. This organization has conducted research to improve access and quality of care for these Plain Communities. There is an apparent need for a similar understanding and relationship with the Plain Communities of western Pennsylvania. Currently, a barrier exists for identifying and ascertaining appropriate individuals within the Plain Community for new research studies. This is largely due to their social and geographical isolation related to religious and cultural practices. Improving research and understanding within Plain Communities has the potential to improve early diagnosis, interventions, and clinical outcomes. Creating an ongoing registry will moderate these barriers and provide a platform for contacting willing members of the Plain Community for participation in future research projects that may positively impact their medical care, as well as the general care in their communities. This is not a study but a registry. Potential participants will be educated about the intent of the registry, and written informed consent will be obtained to allow for collection and storage of information in the registry for an indefinite period of time. At the time of consent, potential participants will be informed about what it means to be a part of the registry and the potential for contact and recruitment to future research studies. One-on-one interviews with a clinician, or with primary and co-investigators, will be conducted. This interview may take place in a clinic setting or the participants home or regional environment. The primary goal of the interview will be to collect a detailed family and medical history of each participant. This will be used to build a detailed pedigree of members of this community. Medical information obtained through released medical records will be included in the registry. Basic demographic and contact information will also be included in the registry. Subjects information will be stored in the host PhenoTips database and data will be regularly undated and reviewed. Participants may be contacted for future research studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02990572
Study type Observational [Patient Registry]
Source University of Pittsburgh
Contact Cate Walsh Vockley, MS, LCGC
Phone 412-692-7349
Email catherine.walshvockley@chp.edu
Status Recruiting
Phase
Start date October 2016
Completion date December 2030

See also
  Status Clinical Trial Phase
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Recruiting NCT05009537 - Optical Genome Mapping in Hematological Malignancies
Terminated NCT01230788 - Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT05461625 - ACL Reconstruction With/Without ALL Reconstruction N/A
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Recruiting NCT04601584 - GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Phase 1/Phase 2
Not yet recruiting NCT05592470 - commd7 Gene Expression in ALL
Recruiting NCT02861209 - Collaborative Network to Take Responsibility for Oral Anticancer Therapy N/A
Completed NCT01012492 - Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Phase 2
Recruiting NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT05476770 - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Phase 1
Recruiting NCT03571321 - Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Active, not recruiting NCT03154346 - Project Baseline Health Study
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1